NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.tizianalifesciences.comTiziana Life Sciences LTD anticipates the completion of its clinical trial for nasal foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis (NCT06890923) on August 30, 2026. The Phase II trial will evaluate the safety and potential efficacy of this treatment, focusing on immunologic response and clinical effects after six months of administration. It is currently recruiting 55 participants, and the results may have implications for treatment options in MS. More details can be found at the trial's website.
Expected Clinical Trial Completion DateTLSA is conducting a clinical trial for Foralumab, a human anti-CD3 antibody, which aims to assess its safety and efficacy in treating Alzheimer's Disease. The study, set to complete by December 1, 2026, will utilize nasal administration of Foralumab in a randomized double-blind placebo-controlled design with two treatment groups receiving different doses. Initial data suggest Foralumab may improve cognition in mouse models of Alzheimer's and it has been well-tolerated in healthy volunteers with progressive multiple sclerosis. The trial is expected to enroll 16 subjects, with screenings occurring at the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston.
Clinical Trial Completion